





Interim Report January – June
2017

556565-5734



We continue to build a new global leader in the field of patient monitoring.



Financial information second quarter 2017

- Net sales amounts to KSEK 174 (521)
- Income after financial items amounts to KSEK -2,930 (-2,024).
- Earnings per share before dilution amounts to SEK -0.07 kr (-0.09).
- Cash and cash equivalents per June 30, 2017 equal SEK 19.5 million (8.0).
- Number of shares per June 30, 2017 amounts to 40,694,223 (32,153,460).

Financial information January – June 2017

- Net sales amounts to KSEK 174 (543).
- Income after financial items amounts to KSEK -6,901 (-3,876).
- Earnings per share before dilution amounts to SEK -0.18 (-0.20).

Definitions. *Earnings per share: Net income for the period divided by the average numbers of shares during the period. In parentheses describes comparative period last year. Unless otherwise stated, all information refers to the Group.*

Significant events during the first quarter

- January 2017. Senzime announces the nomination committee for the AGM 2017. Terry Cross, Sorin Brull, Adam Dahlberg, Ulf Lindskog and Philip Siberg.
- February 2017. Senzime signs distribution agreements for the TetraGraph. Senzime has entered exclusive distribution agreements for the commercialization of TetraGraph in the UK, Ireland, Australia and New Zealand.
- February 2017. The Board of Senzime proposes that an extra general meeting resolves on a rights issue of approximately SEK 24.4 million before issue costs. The rights issue is fully underwritten by the company's principal owner. Concurrently Senzime is planning a listing at Nasdaq First North.
- March 2017. Bulletin from the Extraordinary General Meeting. The shareholders of Senzime have resolved, in accordance with the board's proposal, to issue new shares with pre-emption rights for existing shareholders.
- March 2017. Publication of prospectus regarding the rights issue in Senzime and application for listing on Nasdaq First North.

Significant events during the second quarter

- April 2017. The rights issue was oversubscribed to approximately 103 percent under the original offer. Thus, the company will raise approximately SEK 24.4 million before issue costs, estimated at SEK 3.1 million.
- April 2017. Senzime's first day of trading on Nasdaq First North, April 11, 2017.
- May 2017. Senzime's scientific abstract, "Examining Awake Volunteer Pain Scores and Operator Ease of Use of a Novel Neuromuscular Blockade Monitor" is to be presented at the International Anesthesia Research Society (IARS) meeting in Washington.

- May 2017. Senzime is granted additional patent for OnZurf Probe.
- May 2017. Senzime initiates clinical study with CliniSenz System at Uppsala University Hospital.
- June 2017. Senzime receives ISO 13485 certification which is an important milestone in the CE labeling process.

Significant events after the end of the period

- August 2017. Senzime is awarded a U.S. patent for its TetraSens disposable electrodes.



Statement of the CEO

During the second quarter we continued to strengthen our market positions and the initial commercialization of our product portfolio.

Senzime's quality management system was certified according to ISO 13485, which is an important step and proof that we meet the high standards of quality management for the development, manufacture and sale of medical devices. ISO certification is required by the regulatory framework and is a necessary step for CE marking of Senzime's first three monitoring systems - OnZurf, CliniSenz and TetraGraph.

We are now in the final phase of the comprehensive process of achieving CE approvals and our assessment is that we will receive our first CE approvals in the third quarter of 2017. The CE processes have been challenging and the new, significantly higher requirements for medical device approvals well highlight how high the barriers to entry there are in our markets. Our technical files are based on long-term innovation, research, product development and clinical studies – and will be used to create long-term value in Senzime. Once CE approval is in place, we are ready to take the final step towards a broad market launch of our products in Europe, followed by Japan and the United States.

During the quarter we received a Swedish patent for Onzurf Probe and a US patent for TetraSenz, which is the disposable electrode used in the TetraGraph system. Both patents are important and strategic, since they protect our single-use sensors – the products that are expected to drive the majority of sales and profitability in the long run.

We initiated a clinical study with CliniSenz for local monitoring of lactate after surgery in patients with esophageal cancer, a disease that annually affects approximately 500,000 patients globally.

Also during the quarter, clinical data from the first studies conducted at the Mayo Clinic, USA, were presented. The published results confirmed the user-friendliness of the TetraGraph system and that our now-patented design induces less discomfort from neurostimulation compared to so-called "gold standard" methods.



Demand for systems to easily and objectively determine when it is safe to wake the patient after surgery is high, and it is confirmed by the many published research studies in the field. Equally important is to ensure proper dosage of drugs during surgery and early detection of surgical complications. Our patient monitoring system makes it possible to reduce the proportion of complications and reduce costs in health care.

We are looking forward to a continued eventful and successful year!

Uppsala, August 2017

Lena Söderström, CEO of Senzime AB (publ)

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com



Vallvägen 4A, 756 51 Uppsala
www.senzime.com

Consolidated Income Statement

KSEK	Note	Q2 2017	Q2 2016	Jan-jun 2017	Jan-jun 2016	Full year 2016
Sales revenue		174	521	174	543	1,628
Cost of goods sold		-82	-134	-213	-262	-526
Gross income		92	387	-39	281	1,102
Selling and administrative expenses	1	-3,054	-2,323	-6,822	-4,074	-10,391
Other operating income		67	1	91	11	54
Other operating expenses		-35	-89	-130	-94	-176
Operating income		-2,930	-2,024	-6,900	-3,876	-9,411
Financial income						
Financial expenses				-1		-1
Total financial items		0	0	-1	0	-1
Income after financial items		-2,930	-2,024	-6,901	-3,876	-9,412
Income tax						
Net income		-2,930	-2,024	-6,901	-3,876	-9,412
Average number of shares before dilution		39,930,222	23,579,204	38,051,432	19,827,967	27,799,346
Average number of shares after dilution		40,066,827	23,692,247	38,188,274	19,924,661	27,900,336
Earnings per share before dilution, SEK		-0.07	-0.09	-0.18	-0.20	-0.34
Earnings per share after dilution, SEK		-0.07	-0.09	-0.18	-0.20	-0.34

Consolidated Balance sheet

KSEK	Note	30 jun 2017	30 jun 2016	31 dec 2016
ASSETS				
Non-current assets				
Intangible assets		148,683	139,932	144,809
Machinery and equipment		40	54	47
Total non-current assets		148,723	139,986	144,856
Current assets				
Inventories		1,071	448	373
Accounts receivables		195	39	206
Other current assets		304	15,755	482
Prepaid expenses and accrued income		254	279	368
Cash and cash equivalents		19,482	7,971	10,027
Total current assets		21,306	24,492	11,456
TOTAL ASSETS		170,029	164,478	156,312
EQUITY AND LIABILITIES				
Equity		146,225	137,058	131,871
Provisions		21,123	21,133	21,133
Current liabilities				
Borrowings		-	-	-
Accounts payable		1,226	4,389	1,685
Other liabilities		314	327	228
Accrued expenses and prepaid income		1,141	1,571	1,395
Total current liabilities		2,681	6,287	3,308
TOTAL EQUITY AND LIABILITIES	2	40,236,856	164,478	38,344,586

Consolidated Statement of Changes in Equity

KSEK	Equity	Unregistered share issue	Other contributed capital	Acc exchange rate diff	Retained earnings	Total equity
Opening balance at January 1, 2016	40,192		38,245		-32,627	45,810
Net income					-3,876	-3,876
Exchange rate differences on translation of foreign subsidiaries				183		183
Reduction equity	-38,182				38,182	-
Issue for non-cash consideration (Acquisition Acacia)	2,009		79,982			81,991
Rights issue		15,273				15,273
Issue expenses		-2,323				-2,323
Total equity at June 30, 2016	4,019	12,950	118,227	183	1,679	137,058
Opening balance at January 1, 2017	4,521		130,663	544	-3,857	131,871
Net income					-6,901	-6,901
Exchange rate differences on translation of foreign subsidiaries				224		224
Rights issue	565		23,835			24,400
Issue expenses			-3,369			-3,369
Total equity at June 30, 2017	5,086	-	151,129	768	-10,758	146,225

Consolidated Statement of Cash Flows

KSEK	Note	Q2 2017	Q2 2016	Jan-jun 2017	Jan-jun 2016	Full year 2016
	40,066,827		38,188,274			
Operating cash flow						
Income after financial items		-2,930	-2,024	0	-3,876	-9,412
Adjustment for depreciations		87	169	174	338	678
Other adjustments for items not included in cash flow		38	182	127	182	-213
Cash flow after operating activities before changes in working capital		-2,805	-1,673	-6,600	-3,356	-8,947
Cash flow from changes in working capital						
Changes in inventories and work in progress		-715	-4	-698	44	119
Changes in current receivables		272	-1,362	303	-1,389	678
Changes in current liabilities		141	879	-627	1,125	-1,854
Cash flow from operating activities		-3,107	-2,160	-7,622	-3,576	-10,004
Investing activities						
Acquisition of intangible fixed assets		-2,224	-988	-3,954	-2,074	-6,528
Acquisition of tangible fixed assets			-28		-28	-28
Acquisition of subsidiaries net of cash and cash equivalents			-793		-793	-793
Cash flow from investing activities		-2,224	-1,809	-3,954	-2,895	-7,349
Financing activities						
New issue		21,031		21,031		12,938
New loan and loan amortisation			-	-	-37	-37
Cash flow from financing activities		21,031	0	21,031	-37	12,901
Changes in cash and cash equivalents		15,700	-3,969	9,455	-6,508	-4,452
Cash and cash equivalents at the start of the period		3,782	11,940	10,027	14,479	14,479
Cash and cash equivalents at the end of the period		19,482	7,971	19,482	7,971	10,027

Parent Company Income Statement

KSEK	Note	Q2 2017	Q2 2016	Jan-jun 2017	Jan-jun 2016	Full year 2016
Sales revenue		174	86	174	108	368
Cost of goods sold		-82	-117	-213	-245	-509
Gross income		92	-31	-39	-137	-141
Selling and administrative expenses	1	-2,955	-2,192	-6,608	-3,811	-9,643
Other operating income		67	1	91	12	54
Other operating expenses		-11	-14	-73	-19	-115
Operating income		-2,807	-2,236	-6,629	-3,955	-9,845
Financial income						
Financial expenses		-	-	-1	-	-1
Total financial items		0	0	-1	0	-1
Income after financial items		-2,807	-2,236	-6,630	-3,955	-9,846
Net income		-2,807	-2,236	-6,630	-3,955	-9,846

Parent Company Balance sheet

KSEK	Note	30 jun 2017	30 jun 2016	31 dec 2016
ASSETS				
Non-current assets				
Intangible assets		39,344	32,116	35,558
Machinery and equipment		40	54	47
Financial assets		88,101	85,118	87,839
Total non-current assets		127,485	117,288	123,444
Current assets				
Inventories		1,071	448	373
Accounts receivables		195	9	202
Other current assets		297	15,553	457
Prepaid expenses and accrued income		254	279	368
Cash and cash equivalents		19,453	7,351	9,949
Total current assets		21,270	23,640	11,349
TOTAL ASSETS		148,755	140,928	134,793
EQUITY AND LIABILITIES				
Equity		145,469	136,971	131,068
Provisions		500	500	500
Current liabilities				
Borrowings				
Accounts payable		1,512	2,396	1,821
Other liabilities		352	327	226
Accrued expenses and prepaid income		922	734	1,178
Total current liabilities		2,786	3,457	3,225
TOTAL EQUITY AND LIABILITIES	2	40,215,582	140,928	38,323,067

Parent Company Statement of Changes in Equity

KSEK	Equity	Unregistered share issue	Statutory reserve	Development fund	Share premium reserve	Retained earnings	Total equity
Opening balance at January 1, 2016	40,192		3,839		34,406	-32,452	45,985
Net income						-3,955	-3,955
Capitalization of development costs				1,474	-1,474		0
Reduction equity	-38,182					38,182	0
Issue for non-cash consideration (Acquisition Acacia)	2,009				79,982		81,991
Rights issue		15,273					15,273
Issue expenses		-2,323					-2,323
Total equity at June 30, 2016	4,019	12,950	3,839	1,474	112,914	1,775	136,971
Opening balance at January 1, 2017	4,521		3,839	5,084	121,740	-4,116	131,068
Net income						-6,630	-6,630
Capitalization of development costs				3,954	-3,954		-
New share issue	565				23,835		24,400
Issue expenses					-3,369		3,369
Total equity at June 30, 2017	5,086	-	3,839	9,038	138,252	-10,746	145,469

Parent Company Statement of Cash Flows

KSEK	Note	Q2 2017	Q2 2016	Jan-jun 2017	Jan-jun 2016	Full year 2016
Operating cash flow						
Total financial items		-2,807	-2,236	-6,630	-3,955	-9,846
Adjustment for depreciations		87	86	174	172	348
Cash flow after operating activities before changes in working capital		-2,720	-2,150	-6,456	-3,783	-9,498
Cash flow from changes in working capital						
Changes in inventories and work in progress		-715	-4	-698	44	119
Changes in current receivables		273	-2,326	281	-2,373	-509
Changes in current liabilities		122	1,765	-439	2,030	1,798
Cash flow from operating activities		-3,040	-2,715	-7,312	-4,082	-8,090
Investing activities						
Acquisition of intangible fixed assets		-2,224	-388	-3,954	-1,474	-5,084
Acquisition of tangible fixed assets			-28		-28	-28
Acquisition of financial assets		-70	-507	-261	-507	-3,229
Acquisition of subsidiaries			-866		-866	-866
Cash flow from investing activities		-2,294	-1,789	-4,215	-2,875	-9,207
Financing activities						
New issue		21,031		21,031		12,938
New loan and loan amortisation		-	-	-	-37	-37
Cash flow from financing activities		21,031	0	21,031	-37	12,901
Changes in cash and cash equivalents		15,697	-4,504	9,504	-6,994	-4,396
Cash and cash equivalents at the start of the period		3,756	11,855	9,949	14,345	14,345
Cash and cash equivalents at the end of the period		19,453	7,351	19,453	7,351	9,949

NOTE 1 - Selling and administrative expenses

	Q2	Q2	Jan-jun	Jan-jun	Full year
KSEK	2017	2016	2017	2016	2016
Salaries	1,037	699	2,361	1,596	3,542
Office expenses	94	96	197	200	396
Consultants	1,423	1,007	3,215	1,452	4,808
Travelling expenses	214	134	396	212	524
Marketing expenses	137	216	306	275	423
Depreciation	86	85	172	170	342
Other expenses	63	86	175	169	356
Total selling and administrative expenses	3,054	2,323	6,822	4,074	10,391

NOTE 2 - Pledged assets and contingent liabilities

	Q2	Q2	Jan-jun	Jan-jun	Full year
KSEK	2017	2016	2017	2016	2016
Pledged assets					
For own liabilities and provisions					
Financial guarantees	300	300	300	300	300
Total pledged assets	300	300	300	300	300
Contingent liabilities	None	None			None



Vallvägen 4A, 756 51 Uppsala
www.senzime.com

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on August 31st 2017.